Mylan announced Thursday that it had launched its generic version of Valeant’s Targretin (bexarotene) 75-mg capsules.
Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.
Valeant Pharmaceuticals has bought rights to a drug used to treat skin cancer from Eisai, the companies said Thursday.
Seattle Genetics and Takeda's cancer drug subsidiary have started a late-stage clinical trial for a lymphoma drug, the companies said Wednesday.
The Food and Drug Administration has accepted the first regulatory approval application for a generic version of a cancer drug made by Eisai.